Carsten Nieder1,2, Nicolaus H Andratschke3, Anca L Grosu4. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. 3. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. 4. Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany.
Abstract
BACKGROUND: Historically, radiation oncologists have been cautious about re-irradiating brain tumors because of concerns about the risks of late central nervous system (CNS) toxicity, especially radionecrosis, that may occur several months to years following treatment. Today there are still limited prospective data addressing this approach. MATERIALS AND METHODS: Systematic review of published trials reporting clinical results after re-irradiation of patients with different types of brain tumors was performed. RESULTS: Data mainly related to glioblastoma, anaplastic glioma, medulloblastoma, ependymoma and meningioma have been published. Randomized studies are scarce. As in first-line scenarios, efficacy of radiotherapy is influenced by histology. Based on the reported outcomes, preliminary recommendations for dose/fractionation regimens can be given. CONCLUSION: Re-irradiation of brain tumors is increasingly considered as our understanding of brain tolerance to radiation evolves and developments in radiation technology and imaging make highly accurate targeting of recurrent tumors possible. With developments in systemic therapy, further exploration of the role of re-irradiation on its own or in combination with novel agents is needed. Copyright
BACKGROUND: Historically, radiation oncologists have been cautious about re-irradiating brain tumors because of concerns about the risks of late central nervous system (CNS) toxicity, especially radionecrosis, that may occur several months to years following treatment. Today there are still limited prospective data addressing this approach. MATERIALS AND METHODS: Systematic review of published trials reporting clinical results after re-irradiation of patients with different types of brain tumors was performed. RESULTS: Data mainly related to glioblastoma, anaplastic glioma, medulloblastoma, ependymoma and meningioma have been published. Randomized studies are scarce. As in first-line scenarios, efficacy of radiotherapy is influenced by histology. Based on the reported outcomes, preliminary recommendations for dose/fractionation regimens can be given. CONCLUSION: Re-irradiation of brain tumors is increasingly considered as our understanding of brain tolerance to radiation evolves and developments in radiation technology and imaging make highly accurate targeting of recurrent tumors possible. With developments in systemic therapy, further exploration of the role of re-irradiation on its own or in combination with novel agents is needed. Copyright
Authors: Francesco Cuccia; Gianluca Mortellaro; Lucia Ognibene; Giuseppe Craparo; Antonio Lo Casto; Giuseppe Ferrera Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Katharina J Wenger; Marlies Wagner; Se-Jong You; Kea Franz; Patrick N Harter; Michael C Burger; Martin Voss; Michael W Ronellenfitsch; Emmanouil Fokas; Joachim P Steinbach; Oliver Bähr Journal: Oncol Lett Date: 2017-05-25 Impact factor: 2.967
Authors: Roland Goldbrunner; Maximilian Ruge; Martin Kocher; Carolin Weiss Lucas; Norbert Galldiks; Stefan Grau Journal: Dtsch Arztebl Int Date: 2018-05-21 Impact factor: 5.594
Authors: Jigisha P Thakkar; John T Slevin; Charles D Smith; Padmaja Sudhakar; William St Clair; John L Villano Journal: Neuroophthalmology Date: 2017-05-30
Authors: Delphine Garnier; Brian Meehan; Thomas Kislinger; Paul Daniel; Ankit Sinha; Bassam Abdulkarim; Ichiro Nakano; Janusz Rak Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300